{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T21:05:34Z","timestamp":1785359134873,"version":"3.55.0"},"reference-count":79,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T00:00:00Z","timestamp":1776988800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet Microbe"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.lanmic.2026.101443","type":"journal-article","created":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T19:24:13Z","timestamp":1785353053000},"page":"101443","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Advances in development of tuberculosis vaccines and preventive drug therapies: current pipeline, evidence, and access"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0439-6586","authenticated-orcid":false,"given":"Christopher","family":"da Costa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben J","family":"Marais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8360-4376","authenticated-orcid":false,"given":"Delia","family":"Goletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Onyebujoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremiah","family":"Chakaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2487-125X","authenticated-orcid":false,"given":"Gerhard","family":"Walzl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5111-5735","authenticated-orcid":false,"given":"Alimuddin","family":"Zumla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lanmic.2026.101443_bib2","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2025.1578658","article-title":"Global burden and trend of tuberculosis in children and adolescents (under 15 years old) from 1990 to 2021, with projections to 2040","volume":"13","author":"Liang","year":"2025","journal-title":"Front Public Health"},{"key":"10.1016\/j.lanmic.2026.101443_bib3","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/S2352-4642(25)00218-4","article-title":"Potential paediatric tuberculosis incidence and deaths resulting from interruption in programmes supported by international health aid, 2025\u201334: a mathematical modelling study","volume":"9","author":"Menzies","year":"2025","journal-title":"Lancet Child Adolesc Health"},{"key":"10.1016\/j.lanmic.2026.101443_bib4","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.1016\/S2214-109X(24)00383-8","article-title":"Global burden of tuberculous meningitis in children aged 0\u201314 years in 2019: a mathematical modelling study","volume":"13","author":"du Preez","year":"2025","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.lanmic.2026.101443_bib5","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1038\/s41564-024-01683-0","article-title":"Rethinking the burden of latent tuberculosis to reprioritize research","volume":"9","author":"Behr","year":"2024","journal-title":"Nat Microbiol"},{"key":"10.1016\/j.lanmic.2026.101443_bib6","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1004920","article-title":"Estimating the global burden of viable Mycobacterium tuberculosis infection: a mathematical modelling study","volume":"23","author":"Schwalb","year":"2026","journal-title":"PLoS Med"},{"key":"10.1016\/j.lanmic.2026.101443_bib7","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1056\/NEJMra1405427","article-title":"Latent Mycobacterium tuberculosis infection","volume":"372","author":"Getahun","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lanmic.2026.101443_bib8","article-title":"Revisiting the timetable of tuberculosis","volume":"362","author":"Behr","year":"2018","journal-title":"BMJ"},{"key":"10.1016\/j.lanmic.2026.101443_bib10","doi-asserted-by":"crossref","DOI":"10.1111\/apa.70182","article-title":"The paediatric BCG vaccine century: from historical success to future innovations","author":"Kaufmann","year":"2025","journal-title":"Acta Paediatr"},{"key":"10.1016\/j.lanmic.2026.101443_bib11","doi-asserted-by":"crossref","first-page":"e1307","DOI":"10.1016\/S2214-109X(22)00283-2","article-title":"Infant BCG vaccination and risk of pulmonary and extrapulmonary tuberculosis throughout the life course: a systematic review and individual participant data meta-analysis","volume":"10","author":"Martinez","year":"2022","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.lanmic.2026.101443_bib12","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.g4643","article-title":"Effect of BCG vaccination against Mycobacterium tuberculosis infection in children: systematic review and meta-analysis","volume":"349","author":"Roy","year":"2014","journal-title":"BMJ"},{"key":"10.1016\/j.lanmic.2026.101443_bib13","doi-asserted-by":"crossref","DOI":"10.1093\/ije\/dyaf186","article-title":"Efficacy of Bacillus Calmette\u2013Gu\u00e9rin revaccination in preventing tuberculosis disease: a systematic review and meta-analysis","volume":"54","author":"Rossi","year":"2025","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.lanmic.2026.101443_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.lanmic.2024.100961","article-title":"Effectiveness of the primary Bacillus Calmette\u2013Gu\u00e9rin vaccine against the risk of Mycobacterium tuberculosis infection and tuberculosis disease: a meta-analysis of individual participant data","volume":"6","author":"Pelzer","year":"2025","journal-title":"Lancet Microbe"},{"key":"10.1016\/j.lanmic.2026.101443_bib15","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s40265-024-02131-3","article-title":"Tuberculosis preventive treatment in high TB-burden settings: a state-of-the-art review","volume":"85","author":"Chihota","year":"2025","journal-title":"Drugs"},{"key":"10.1016\/j.lanmic.2026.101443_bib16","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/S2213-2600(23)00096-6","article-title":"Completion, safety, and efficacy of tuberculosis preventive treatment regimens containing rifampicin or rifapentine: an individual patient data network meta-analysis","volume":"11","author":"Winters","year":"2023","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.lanmic.2026.101443_bib17","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1056\/NEJMoa1104875","article-title":"Three months of rifapentine and isoniazid for latent tuberculosis infection","volume":"365","author":"Sterling","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lanmic.2026.101443_bib18","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJMoa1806808","article-title":"One month of rifapentine plus isoniazid to prevent HIV-related tuberculosis","volume":"380","author":"Swindells","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lanmic.2026.101443_bib19","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1005136","article-title":"New regimens to prevent tuberculosis in adults with HIV infection","volume":"365","author":"Martinson","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lanmic.2026.101443_bib20","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1056\/NEJMoa1714283","article-title":"Four months of rifampin or nine months of isoniazid for latent tuberculosis in adults","volume":"379","author":"Menzies","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lanmic.2026.101443_bib21","doi-asserted-by":"crossref","first-page":"e692","DOI":"10.1016\/S1473-3099(25)00157-4","article-title":"Management of individuals exposed to multidrug-resistant or rifampicin-resistant tuberculosis","volume":"25","author":"Seddon","year":"2025","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.lanmic.2026.101443_bib22","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/S0140-6736(25)02433-X","article-title":"Global tuberculosis response off track: urgent priorities to end the world\u2019s top infectious killer","volume":"407","author":"Hui","year":"2026","journal-title":"Lancet"},{"key":"10.1016\/j.lanmic.2026.101443_bib24","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/S1473-3099(19)30307-X","article-title":"Global burden of latent multidrug-resistant tuberculosis: trends and estimates based on mathematical modelling","volume":"19","author":"Knight","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.lanmic.2026.101443_bib25","doi-asserted-by":"crossref","first-page":"e228","DOI":"10.1016\/S1473-3099(18)30134-8","article-title":"Progression from latent infection to active disease in dynamic tuberculosis transmission models: a systematic review of the validity of modelling assumptions","volume":"18","author":"Menzies","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.lanmic.2026.101443_bib26","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/S1473-3099(18)30421-3","article-title":"WHO preferred product characteristics for new vaccines against tuberculosis","volume":"18","author":"Schrager","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.lanmic.2026.101443_bib28","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/S0140-6736(13)60177-4","article-title":"Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial","volume":"381","author":"Tameris","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.lanmic.2026.101443_bib29","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1056\/NEJMoa1909953","article-title":"Final analysis of a trial of M72\/AS01E vaccine to prevent tuberculosis","volume":"381","author":"Tait","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lanmic.2026.101443_bib32","author":"Frick"},{"key":"10.1016\/j.lanmic.2026.101443_bib34","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2025.2469333","article-title":"RNA vaccines: the dawn of a new age for tuberculosis?","volume":"21","author":"Li","year":"2025","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.lanmic.2026.101443_bib35","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/S2213-2600(15)00435-X","article-title":"Safety of human immunisation with a live-attenuated Mycobacterium tuberculosis vaccine: a randomised, double-blind, controlled phase I trial","volume":"3","author":"Spertini","year":"2015","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.lanmic.2026.101443_bib36","volume":"14","author":"Singh","year":"2024","journal-title":"BMJ Open"},{"key":"10.1016\/j.lanmic.2026.101443_bib37","doi-asserted-by":"crossref","first-page":"652","DOI":"10.3390\/vaccines8040652","article-title":"Safety and immunogenicity of the GamTBvac, the recombinant subunit tuberculosis vaccine candidate: a phase II, multi-center, double-blind, randomized, placebo-controlled study","volume":"8","author":"Tkachuk","year":"2020","journal-title":"Vaccines"},{"key":"10.1016\/j.lanmic.2026.101443_bib38","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2025-085716","article-title":"Efficacy and safety of VPM1002 and Immuvac in preventing tuberculosis: phase 3 randomised clinical trial (PreVenTB trial)","volume":"393","author":"Singh","year":"2026","journal-title":"BMJ"},{"key":"10.1016\/j.lanmic.2026.101443_bib39","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/s41585-021-00481-1","article-title":"100 years of Bacillus Calmette-Gu\u00e9rin immunotherapy: from cattle to COVID-19","volume":"18","author":"Lobo","year":"2021","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.lanmic.2026.101443_bib40","doi-asserted-by":"crossref","first-page":"7239","DOI":"10.1016\/j.vaccine.2020.09.055","article-title":"DAR-901 vaccine for the prevention of infection with Mycobacterium tuberculosis among BCG-immunized adolescents in Tanzania: a randomized controlled, double-blind phase 2b trial","volume":"38","author":"Munseri","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.lanmic.2026.101443_bib41","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/j.vaccine.2009.09.134","article-title":"Double-blind, randomized, placebo-controlled phase I clinical trial of the therapeutical antituberculous vaccine RUTI","volume":"28","author":"Vilaplana","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.lanmic.2026.101443_bib42","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/S2213-2600(18)30077-8","article-title":"Safety and immunogenicity of the novel tuberculosis vaccine ID93 + GLA-SE in BCG-vaccinated healthy adults in South Africa: a randomised, double-blind, placebo-controlled phase 1 trial","volume":"6","author":"Penn-Nicholson","year":"2018","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.lanmic.2026.101443_bib43","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0217091","article-title":"CD4+ T cell cytokine responses to the DAR-901 booster vaccine in BCG-primed adults: a randomized, placebo-controlled trial","volume":"14","author":"Masonou","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.lanmic.2026.101443_bib44","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0175215","article-title":"Safety and immunogenicity of an inactivated whole cell tuberculosis vaccine booster in adults primed with BCG: a randomized, controlled trial of DAR-901","volume":"12","author":"von Reyn","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.lanmic.2026.101443_bib45","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/nm.2285","article-title":"A multistage tuberculosis vaccine that confers efficient protection before and after exposure","volume":"17","author":"Aagaard","year":"2011","journal-title":"Nat Med"},{"key":"10.1016\/j.lanmic.2026.101443_bib46","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa1714021","article-title":"Prevention of M. tuberculosis infection with H4:IC31 vaccine or BCG revaccination","volume":"379","author":"Nemes","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lanmic.2026.101443_bib47","doi-asserted-by":"crossref","first-page":"4130","DOI":"10.1016\/j.vaccine.2015.06.051","article-title":"First-in-human trial of the post-exposure tuberculosis vaccine H56:IC31 in Mycobacterium tuberculosis infected and non-infected healthy adults","volume":"33","author":"Luabeya","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.lanmic.2026.101443_bib48","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.vaccine.2019.10.072","article-title":"Preferred product characteristics for therapeutic vaccines to improve tuberculosis treatment outcomes: key considerations from World Health Organization consultations","volume":"38","author":"Vekemans","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.lanmic.2026.101443_bib49","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/s41591-022-02110-9","article-title":"T cell receptor repertoires associated with control and disease progression following Mycobacterium tuberculosis infection","volume":"29","author":"Musvosvi","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.lanmic.2026.101443_bib50","doi-asserted-by":"crossref","DOI":"10.1128\/mbio.03232-25","article-title":"Targeting the lung innate pathways during tuberculosis can improve vaccine-induced protection via Th17 responses in diversity outbred mice","volume":"17","author":"Ahmed","year":"2026","journal-title":"mBio"},{"key":"10.1016\/j.lanmic.2026.101443_bib51","doi-asserted-by":"crossref","first-page":"6791","DOI":"10.1016\/j.cell.2025.08.027","article-title":"Mining the CD4 antigen repertoire for next-generation tuberculosis vaccines","volume":"188","author":"Vidal","year":"2025","journal-title":"Cell"},{"key":"10.1016\/j.lanmic.2026.101443_bib52","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/joim.70028","article-title":"T cell-macrophage interactions in tuberculosis: what we\u2019ve got here is failure to communicate","volume":"299","author":"Mortensen","year":"2026","journal-title":"J Intern Med"},{"key":"10.1016\/j.lanmic.2026.101443_bib53","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1006687","article-title":"Sequential inflammatory processes define human progression from M. tuberculosis infection to tuberculosis disease","volume":"13","author":"Scriba","year":"2017","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.lanmic.2026.101443_bib54","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1186\/s12916-023-02992-7","article-title":"New tuberculosis vaccines in India: modelling the potential health and economic impacts of adolescent\/adult vaccination with M72\/AS01E and BCG-revaccination","volume":"21","author":"Clark","year":"2023","journal-title":"BMC Med"},{"key":"10.1016\/j.lanmic.2026.101443_bib55","doi-asserted-by":"crossref","DOI":"10.1128\/CVI.00439-16","article-title":"Safety and immunogenicity of the recombinant Mycobacterium bovis BCG vaccine VPM1002 in HIV-unexposed newborn infants in South Africa","volume":"24","author":"Loxton","year":"2017","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.lanmic.2026.101443_bib56","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.ebiom.2016.04.010","article-title":"Safety and immunogenicity of the recombinant BCG vaccine AERAS-422 in healthy BCG-na\u00efve adults: a randomized, active-controlled, first-in-human phase 1 trial","volume":"7","author":"Hoft","year":"2016","journal-title":"EBioMedicine"},{"key":"10.1016\/j.lanmic.2026.101443_bib57","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.3389\/fimmu.2017.01147","article-title":"The recombinant Bacille Calmette-Gu\u00e9rin vaccine VPM1002: ready for clinical efficacy testing","volume":"8","author":"Nieuwenhuizen","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.lanmic.2026.101443_bib58","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/S1473-3099(24)00814-4","volume":"25","author":"Borges","year":"2025","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.lanmic.2026.101443_bib59","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/S2213-2600(25)00164-X","article-title":"Evidence required to evaluate the use of bacteriologically confirmed asymptomatic tuberculosis disease as a primary endpoint in prevention of tuberculosis disease vaccine licensure trials","volume":"13","author":"White","year":"2025","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.lanmic.2026.101443_bib60","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1056\/NEJMoa2412381","article-title":"BCG revaccination for the prevention of Mycobacterium tuberculosis infection","volume":"392","author":"Schmidt","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lanmic.2026.101443_bib61","doi-asserted-by":"crossref","DOI":"10.1172\/JCI175264","article-title":"Immune mechanisms of granuloma formation in sarcoidosis and tuberculosis","volume":"134","author":"Weeratunga","year":"2024","journal-title":"J Clin Invest"},{"key":"10.1016\/j.lanmic.2026.101443_bib62","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1093\/infdis\/jiaf277","article-title":"Sex differences in vaccine-induced immunity and protection against Mycobacterium tuberculosis","volume":"232","author":"Harikumar Parvathy","year":"2025","journal-title":"J Infect Dis"},{"key":"10.1016\/j.lanmic.2026.101443_bib63","doi-asserted-by":"crossref","first-page":"e1517","DOI":"10.1016\/S2214-109X(25)00232-3","article-title":"The potential impact of reductions in international donor funding on tuberculosis in low-income and middle-income countries: a modelling study","volume":"13","author":"Clark","year":"2025","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.lanmic.2026.101443_bib64","doi-asserted-by":"crossref","DOI":"10.1016\/j.lanmic.2026.101442","article-title":"Advances in tuberculosis treatment: novel regimens, new drug pipelines, host-directed therapies, and updated management guidelines","author":"Marais","year":"2026","journal-title":"Lancet Microbe"},{"key":"10.1016\/j.lanmic.2026.101443_bib65","doi-asserted-by":"crossref","first-page":"e401","DOI":"10.1093\/cid\/ciaf284","article-title":"Risk of tuberculosis infection in young children exposed to multidrug-resistant tuberculosis in the TB-CHAMP multi-site randomized controlled trial","volume":"81","author":"Purchase","year":"2025","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.lanmic.2026.101443_bib66","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1056\/NEJMoa2314325","article-title":"Levofloxacin for the prevention of multidrug-resistant tuberculosis in Vietnam","volume":"391","author":"Fox","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lanmic.2026.101443_bib67","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1056\/NEJMoa2314318","article-title":"Levofloxacin preventive treatment in children exposed to MDR tuberculosis","volume":"391","author":"Hesseling","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lanmic.2026.101443_bib68","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciaf701","article-title":"Implementing a program of comprehensive tuberculosis preventive treatment: safety, effectiveness, and acceptability of moxifloxacin or bedaquiline use for contacts exposed to drug-resistant strains","author":"Solovyeva","year":"2026","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.lanmic.2026.101443_bib69","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2400190","article-title":"A meta-analysis of levofloxacin for contacts of multidrug-resistant tuberculosis","volume":"4","author":"Duong","year":"2025","journal-title":"NEJM Evid"},{"key":"10.1016\/j.lanmic.2026.101443_bib70","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.3201\/eid3112.250492","article-title":"Pregnancy outcomes after exposure to tuberculosis treatment in Phase 3 clinical trial, 2016\u20132020","volume":"31","author":"Kurbatova","year":"2025","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.lanmic.2026.101443_bib71","doi-asserted-by":"crossref","first-page":"120","DOI":"10.5588\/ijtldopen.24.0467","article-title":"An open-label cluster-randomised trial on TB preventive therapy for children","volume":"2","author":"Lemvik","year":"2025","journal-title":"IJTLD Open"},{"key":"10.1016\/j.lanmic.2026.101443_bib72","doi-asserted-by":"crossref","first-page":"13","DOI":"10.5588\/ijtldopen.24.0250","article-title":"Children and providers\u2019 perspectives on once-weekly rifapentine and isoniazid TB preventive therapy","volume":"2","author":"Marthinus","year":"2025","journal-title":"IJTLD Open"},{"key":"10.1016\/j.lanmic.2026.101443_bib73","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1186\/s12879-025-10832-7","article-title":"Treatment completion and safety profile of once-weekly 3HP regimen for tuberculosis preventive treatment in children and adolescents: a systematic review","volume":"25","author":"Pangprasertkul","year":"2025","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.lanmic.2026.101443_bib74","doi-asserted-by":"crossref","first-page":"e580","DOI":"10.1093\/cid\/ciac707","article-title":"Rifapentine with and without moxifloxacin for pulmonary tuberculosis in people with human immunodeficiency virus (S31\/A5349)","volume":"76","author":"Pettit","year":"2023","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.lanmic.2026.101443_bib75","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/S1473-3099(18)30355-4","article-title":"Prognostic value of interferon-\u03b3 release assays and tuberculin skin test in predicting the development of active tuberculosis (UK PREDICT TB): a prospective cohort study","volume":"18","author":"Abubakar","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.lanmic.2026.101443_bib76","doi-asserted-by":"crossref","DOI":"10.1080\/25310429.2025.2482855","article-title":"European guidelines for the management of tuberculosis screening procedures in migrants: a systematic review","volume":"31","author":"Pinheiro","year":"2025","journal-title":"Pulmonology"},{"key":"10.1016\/j.lanmic.2026.101443_bib77","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.02822-25","article-title":"Demographic and clinical correlates of discordant QuantiFERON TB Gold tuberculosis screening results in a low-incidence setting","volume":"14","author":"Sharma","year":"2026","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.lanmic.2026.101443_bib79","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1164\/rccm.202410-2096ST","article-title":"Updates on the treatment of drug-susceptible and drug-resistant tuberculosis: an official ATS\/CDC\/ERS\/IDSA clinical practice guideline","volume":"211","author":"Saukkonen","year":"2025","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.lanmic.2026.101443_bib83","article-title":"CD8+ lymphocytes in immunity against tuberculosis","volume":"215","author":"Li","year":"2026","journal-title":"J Immunol"},{"key":"10.1016\/j.lanmic.2026.101443_bib84","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1016\/S0140-6736(15)01316-1","article-title":"A blood RNA signature for tuberculosis disease risk: a prospective cohort study","volume":"387","author":"Zak","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.lanmic.2026.101443_bib85","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S2213-2600(16)00048-5","article-title":"Genome-wide expression for diagnosis of pulmonary tuberculosis: a multicohort analysis","volume":"4","author":"Sweeney","year":"2016","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.lanmic.2026.101443_bib86","article-title":"TB vaccine development: monitoring international patent filings to anticipate access challenges","volume":"13","author":"Pignataro","year":"2025","journal-title":"Front Public Health"},{"key":"10.1016\/j.lanmic.2026.101443_bib87","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S1473-3099(25)00666-8","article-title":"G20 2025: advancing equity and affordability in future tuberculosis vaccines for adolescents and adults","volume":"25","author":"Ghebreyesus","year":"2025","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.lanmic.2026.101443_bib89","doi-asserted-by":"crossref","first-page":"e385","DOI":"10.1093\/cid\/ciaf203","article-title":"Effectiveness of a home-based approach to child contact investigation and tuberculosis preventive treatment management by community health workers in Ethiopia: a pragmatic cluster-randomized trial","volume":"81","author":"Salazar-Austin","year":"2025","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.lanmic.2026.101443_bib90","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgph.0005047","article-title":"Insights on the implementation strategies for a potential new tuberculosis vaccine in South Africa","volume":"6","author":"Thomas","year":"2026","journal-title":"PLoS Glob Public Health"},{"key":"10.1016\/j.lanmic.2026.101443_bib92","series-title":"Global Fund Partnership and Health Systems","year":"2025"}],"container-title":["The Lancet Microbe"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666524726000984?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666524726000984?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T20:52:47Z","timestamp":1785358367000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666524726000984"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":79,"alternative-id":["S2666524726000984"],"URL":"https:\/\/doi.org\/10.1016\/j.lanmic.2026.101443","relation":{},"ISSN":["2666-5247"],"issn-type":[{"value":"2666-5247","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advances in development of tuberculosis vaccines and preventive drug therapies: current pipeline, evidence, and access","name":"articletitle","label":"Article Title"},{"value":"The Lancet Microbe","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lanmic.2026.101443","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.lanmic.2026.101435","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1016\/j.lanmic.2026.101442","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1016\/j.lanmic.2026.101433","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101443"}}